使用FDA不良事件报告系统数据库对与药物相关的白内障进行现实世界药监分析
Xiang Li1,2, Shu Wen Wang1, Zhi-Jie Zhang1
1Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Frontiers in pharmacology
|May 9, 2025
概括
这项研究确定了15种药物,包括免疫调节剂和抗新生素,作为药物诱导白内障的独立风险因素. 大多数不良事件发生在747天内,有助于早期检测和未来研究.
科学领域:
- 药物监督 药物监督 药物监督
- 眼科医生 眼科 眼科
- 药品安全 药品安全
背景情况:
- 药物诱导的白内障是一种已知的不良影响,但许多药物的风险因素仍然不清楚.
- 大规模的数据分析对于识别潜在的毒品相关风险至关重要.
研究的目的:
- 通过使用现实世界的数据,调查药物诱导白内障的风险因素.
- 确定与白内障风险增加相关的特定药物类别.
主要方法:
- 美国食品和药物管理局不良事件报告系统 (FAERS) 数据库的分析 (2004年第一季度 - 2024年第三季度).
- 使用报告几率比率 (ROR),单变量,LASSO和多变量回归分析.
- 在多次比较中应用了邦费罗尼校正.
主要成果:
- 15种药物被确定为白内障的独立风险因素.
- 关键药物类别包括免疫调节剂 (6/15),抗瘤药物 (3/15),以及各种治疗领域的其他药物.
- 白内障发病的中位时间为449天,75%的事件发生在747天内.
结论:
- 这些发现有助于临床医生早期检测药物诱导的白内障.
- 提供了对潜在机制的见解,并为未来的药物安全研究提供了信息.
相关概念视频
Pharmacovigilance
744
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
744
Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Clinical Trials: Overview
2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K


